

Removal of temporary benefit from the Alberta Drug Benefit List (ADBL)

Due to the shortage of Acetylcysteine 20% Inhalation Solution (DIN 02243098), manufactured by Sandoz Canada Inc, Acetylcysteine 20% Inhalation Solution (DIN 02300435) was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Sandoz Canada Inc. has advised Alberta Blue Cross that the shortage of Acetylcysteine 20% Inhalation Solution (DIN 02243098) has been resolved.

As a result, Acetylcysteine 20% Inhalation Solution (DIN 02300435) will no longer be considered a temporary benefit for the *ADBL* after **February 15, 2016**.

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Sivem Pharmaceuticals ULC and Pharmascience Inc. that the shortages for Telmisartan HCTZ 80 mg/25 mg Tablet (DIN 02390310) and Telmisartan-HCTZ 80 mg/25 mg Tablet (DIN 02433222), respectively, have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 15, 2016**.

TELMISARTAN/ HYDROCHLOROTHIAZIDE

80 MG / 25 MG TABLET

00002419122	ACH-TELMISARTAN HCTZ	AHI	\$ 0.2821
00002420031	APO-TELMISARTAN/HCTZ	APX	\$ 0.2821
00002373572	MYLAN-TELMISARTAN HCTZ	MYP	\$ 0.2821
00002401673	PMS-TELMISARTAN-HCTZ	PMS	\$ 0.2821
00002390310	TELMISARTAN HCTZ	SIV	\$ 0.2821
00002433222	TELMISARTAN-HCTZ	PMS	\$ 0.2821
00002393271	ACT TELMISARTAN/HCT	APH	\$ 0.2914
00002393565	SANDOZ TELMISARTAN HCT	SDZ	\$ 0.2914
00002395363	TELMISARTAN/HCTZ	SNS	\$ 0.2914
00002379252	TEVA-TELMISARTAN HCTZ	TEV	\$ 0.2914
00002318709	MICARDIS PLUS	BOE	\$ 1.1657

... continued from previous page

Alberta Blue Cross has been advised by Mylan Pharmaceuticals ULC. and Teva Limited Canada that the shortages of Mylan-Buprenorphine Naloxone 2 mg/0.5 mg Sublingual Tablet (DIN 02408090) and Teva-Buprenorphine/Naloxone 2 mg/0.5 mg Sublingual Tablet (DIN 02424851) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 18, 2016**.

BUPRENORPHINE HCL/ NALOXONE HYDROCHLORIDE DIHYDRATE

2 MG / 0.5 MG SUBLINGUAL TABLET

00002408090	MYLAN-BUPRENORPHINE NALOXONE	MYP	\$ 1.3350
00002424851	TEVA-BUPRENORPHINE/NALOXONE	TEV	\$ 1.3350
00002295695	SUBOXONE	IUK	\$ 2.6700

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage of pms-Sulfasalazine 500 mg Enteric-Coated Tablet (DIN 00598488) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective February 19, 2016.

SULFASALAZINE

500 MG ENTERIC-COATED TABLET

00000598488	PMS-SULFAZALAZINE	PMS	\$ 0.3530
00002064472	SALAZOPYRIN EN-TABS	PFI	\$ 0.4038

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)
FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

